PRESS RELEASE : Cannovum AG enters cannabis market segment Dronabinol

DGAP-News: Cannovum AG / Key word(s): Product Launch 
Cannovum AG enters cannabis market segment Dronabinol 
2021-06-15 / 10:02 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Cannovum AG (stock markets Düsseldorf, München, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) is pleased to announce a 
strategic supply partnership for Dronabinol with a European medical cannabis supplier. Products are expected to be sold 
starting from August as part of the Cannovum brand range, with a signature supply contract initially running until the 
end of 2023. 
 
Cannovum is expanding its medical cannabis portfolio by adding Dronabinol through its licensed subsidiary, Cannovum 
Health eG. Dronabinol is a synthesized cannabinoid first prescribable in 1998 and now primarily used in pain therapy. 
By adding this established medication to the product portfolio, Cannovum takes another step to ensure best possible 
patient care: only a full range of medical cannabis medication options grants doctors the opportunity to find the 
optimum individual treatment for each patient. 
"The market for dronabinol has a volume of over EUR45 million in Germany alone. The inclusion in our portfolio under our 
own brand is an important milestone to provide patients in Germany and later Europe with a comprehensive range of 
medicinal cannabis. Cannabis extracts are to follow next," says Pia Marten, CEO of Cannovum AG. 
In order to support doctors and pharmacists in finding the best possible treatment, Cannovum's pharmaceutical 
representatives have undergone intensive training on the full spectrum of Dronabinol with established medical 
professionals. Experience and expertise are key components in providing the best possible patient care, because every 
patient deserves the best therapy. 
Contact: 
Linda Rasch, IR & PR, Cannovum AG 
Telefon [phone], [e-mail] 
About Cannovum AG: 
Cannovum AG is the first German listed medical cannabis company. Through its subsidiary Cannovum Health eG, Cannovum is 
a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based 
in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and 
all-encompassing distribution for simplified and facilitated access to cannabis-based therapies. 
For more information, visit www.cannovum.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-15 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Cannovum AG 
              Rheinsberger Str. 76/77 
              10115 Berlin 
              Germany 
Phone:        [phone] 
E-mail:       [e-mail] 
Internet:     www.cannovum.com 
ISIN:         DE000A2LQU21 
WKN:          A2LQU2 
Listed:       Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich 
EQS News ID:  1208107 
 
End of News   DGAP News Service 
=------------ 

1208107 2021-06-15

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1208107&application_name=news

(END) Dow Jones Newswires

June 15, 2021 04:03 ET (08:03 GMT)